Department of Pediatrics, Universidad de Antioquia, Calle 67 # 53-108, 050001, Medellin, Colombia.
Department of Oncology, McMaster University, Juravinski Site, G2 Wing, 1280 Main Street West, Hamilton, Ontario, L8S 4L8, Canada.
Implement Sci. 2020 Sep 18;15(1):79. doi: 10.1186/s13012-020-01036-5.
To assess the quality of recommendations from 161 clinical practice guidelines (CPGs) using AGREE-REX-D (Appraisal of Guidelines REsearch and Evaluation-Recommendations Excellence Draft).
Cross-sectional study SETTING: International CPG community.
Three hundred twenty-two international CPG developers, users, and researchers.
Participants were assigned to appraise one of 161 CPGs selected for the study using the AGREE-REX-D tool MAIN OUTCOME MEASURES: AGREE-REX-D scores of 161 CPGs (7-point scale, maximum 7).
Recommendations from 161 CPGs were appraised by 322 participants using the AGREE-REX-D. CPGs were developed by 67 different organizations. The total overall average score of the CPG recommendations was 4.23 (standard deviation (SD) = 1.14). AGREE-REX-D items that scored the highest were (mean; SD): evidence (5.51; 1.14), clinical relevance (5.95; SD 0.8), and patients/population relevance (4.87; SD 1.33), while the lowest scores were observed for the policy values (3.44; SD 1.53), local applicability (3,56; SD 1.47), and resources, tools, and capacity (3.49; SD 1.44) items. CPGs developed by government-supported organizations and developed in the UK and Canada had significantly higher recommendation quality scores with the AGREE-REX-D tool (p < 0.05) than their comparators.
We found that there is significant room for improvement of some CPGs such as the considerations of patient/population values, policy values, local applicability and resources, tools, and capacity. These findings may be considered a baseline upon which to measure future improvements in the quality of CPGs.
使用 AGREE-REX-D(评估指南研究与评价-建议卓越草案)评估 161 项临床实践指南(CPG)的建议质量。
横断面研究
国际 CPG 社区。
322 名国际 CPG 开发者、用户和研究人员。
参与者被分配评估从研究中选择的 161 项 CPG 中的一项,使用 AGREE-REX-D 工具。
161 项 CPG 的 AGREE-REX-D 评分(7 分制,最高 7 分)。
322 名参与者使用 AGREE-REX-D 评估了 161 项 CPG 的建议。CPG 由 67 个不同的组织开发。CPG 建议的总平均得分为 4.23(标准差(SD)=1.14)。AGREE-REX-D 评分最高的项目是(平均值;SD):证据(5.51;1.14)、临床相关性(5.95;SD 0.8)和患者/人群相关性(4.87;SD 1.33),而政策价值(3.44;SD 1.53)、当地适用性(3.56;SD 1.47)和资源、工具和能力(3.49;SD 1.44)的得分最低。由政府支持的组织开发并在英国和加拿大开发的 CPG 与对照组相比,使用 AGREE-REX-D 工具的建议质量评分显著更高(p < 0.05)。
我们发现,一些 CPG 仍有很大的改进空间,例如考虑患者/人群的价值观、政策价值观、当地适用性以及资源、工具和能力。这些发现可被视为衡量未来 CPG 质量改进的基准。